Immunization News and Research

RSS

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

A team of researchers recently optimized regimens for CVac, wherein aseptic, purified, cryopreserved, and infectious PfSPZ were inoculated and mixed with PYR and CQ.

5 Jul 2021

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

A study conducted by researchers from Maryland in the United States has found no correlation between the symptoms that develop following vaccination against coronavirus disease 2019 (COVID-19) and the antibody responses that are generated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Varenicline blocks SARS-CoV-2 infection in cells and animal models

A new paper released on the bioRxiv* preprint server suggests that the nicotinic acetylcholine receptor (nACHR) agonist, varenicline tartrate, has antiviral activity against the virus.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

COVAX urges equal recognition of all COVID-19 vaccines

COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to travel and conduct trade.

5 Jul 2021

Unprecedented lobbying effort scores big win for California public health

After more than a decade of fruitless entreaties from public health advocates, Democratic lawmakers have secured a landmark agreement that promises $300 million a year in new state funding to fortify and reimagine California's hollowed-out public health system, a complex network of services shouldered largely by the state's 61 local health departments.

2 Jul 2021

Is there a link between circadian rhythms and COVID-19 severity?

This study showed that the time of day of SARS-CoV-2 infection could impact the severity of the viral infection and the host immune response.

1 Jul 2021

Scientists reveal the role of newly introduced lineages in COVID-19 resurgence in Europe

Following the first wave of SARS-CoV-2 infections in spring 2020, Europe experienced a resurgence of the virus starting late summer. Although it appears clear that travel had a significant impact on the circulation of the virus, it remains challenging to assess how it may have restructured and reignited the epidemic in the different European countries.

1 Jul 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Public opinion surveys could be used to understand regional variation in vaccine hesitancy, say experts

Public opinion surveys could be used more widely to understand regional variation in vaccine hesitancy, experts have recommended.

29 Jun 2021

Study suggests vitamin B12 as a SARS-CoV-2 antiviral

Researchers in the UK and Spain have used a novel drug screening approach to identify compounds that could serve as effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

28 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Georgia Tech’s dashboard breaks down Covid-19 vaccination trends by race at county level

The U.S. continues to see Covid-19 vaccinations gradually increasing nationwide, with nearly 66% of all adults now having at least one vaccine dose according to CDC's COVID Data Tracker, yet disparities have been noted in vaccination rates across races and geographic areas.

25 Jun 2021

Could polio vaccines induce cross-reactive antibodies that target SARS-CoV-2?

A new preprint released on the medRxiv* server explores a link between immunity to SARS-CoV-2, the earlier SARS-CoV, and childhood poliovirus vaccination. Almost 90% of the world’s people have received this vaccine, but antibodies elicited by it reduce over time and are almost absent at the end of adolescence.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

SARS-CoV-2 Delta variant likely to become dominant in the United States

Researchers have conducted a study showing that the B.1.1.7 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in the UK is now rapidly being displaced as the dominant strain in the United States by the variants of concern B.1.617.2 (Delta) and P.1 (Gamma) that emerged in India and Brazil, respectively.

23 Jun 2021

Immunization News and Research

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

Varenicline blocks SARS-CoV-2 infection in cells and animal models

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

COVAX urges equal recognition of all COVID-19 vaccines

Unprecedented lobbying effort scores big win for California public health

Is there a link between circadian rhythms and COVID-19 severity?

Scientists reveal the role of newly introduced lineages in COVID-19 resurgence in Europe

Antibody development against SARS-CoV-2 following Moderna vaccine

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Public opinion surveys could be used to understand regional variation in vaccine hesitancy, say experts

Study suggests vitamin B12 as a SARS-CoV-2 antiviral

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Georgia Tech’s dashboard breaks down Covid-19 vaccination trends by race at county level

Could polio vaccines induce cross-reactive antibodies that target SARS-CoV-2?

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

SARS-CoV-2 Delta variant likely to become dominant in the United States

Repeated vaccination could control infection with SARS-CoV-2 variants among infection-naïve individuals

First spatial scan analysis helps identify hotspots of undervaccinated children

Engineering nanobodies to fight against the SARS-CoV-2 virus

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News